secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160387
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phoenix Biotech Acquisition Corp. to merge with CERo Therapeutics in $50M deal
------------------------------------------------------------------------------

- Consideration: ~5.0M shares of Class A common stock (value ~$50M) for CERo holders, plus up to 1.2M earnout shares.
- Closing condition: available cash after redemptions must be at least $30M; termination date Sept 30, 2023, extendable.
- Sponsor (699,996 Class A and 4,596,250 Class B shares) and CERo stockholders entered support agreements to vote in favor.
- Combined company renamed to 'CERo Therapeutics Holdings, Inc.' and will apply to list on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/0001193125-23-160387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/d494471d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer